Tumores de corteza suprarrenal en Paraguay: hallazgos genéticos y conside-raciones a tener en cuenta para el diagnóstico
Palabras clave:
cáncer, tumor de corteza suprarrenal, prevalencia, gen TP53, variante del gen TP53R337H, ParaguayResumen
El tumor de corteza suprarrenal (TCA) es 12 a 18 veces más frecuente en el sur de Brasil que en cualquier otro lugar, siendo una de las causas, la presencia en esta población de la variante del gen TP53R337H. En años recientes, una investigación realizada en el país descubrió que la región fronteriza con Brasil, debido a su alta migración brasileña, también presentó frecuencias de la variante del referido gen similares al sur del Brasil (5/10.000 nacidos vivos). Este trabajo detalla los aspectos genéticos que subyacen al tumor de TCA y las consideraciones para diagnóstico y tratamiento a tener en cuenta debito al índice de la variante detectada.
Citas
Santacruz E, Duarte D, Orué C, Ca-brera N, Benítez G, Cañete F, Sequera VG. Atlas de mortalidad por cáncer en Paraguay: periodo 2015-2019. Asun-ción: DVENT, DGVS, MSPyBS; 2022.
Klein JD, et al. Adrenal cortical tu-mors in children: factors associated with poor outcome. J Pediatr Surg. 2011;46(6):1201-7.
Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA. 2001;98(16):9330-5.
Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with spo-radic adrenocortical tumors. J Clin En-docrinol Metab. 2001;86(10):4970-3.
Bernstein L, Gurney JG. Carcinomas and other malignant epithelial neo-plasms. In: Ries LAG, Smith MA, Gur-ney JG, et al., editors. Cancer and sur-vival among children and adolescents: United States: SEER program 1975–1995. Bethesda, MD: National Cancer Institute; 1999. p. 139-47.
Parkin DM, Kramárová E, Draper GJ, et al. International incidence of childhood cancer, vol. II. IARC Scienti-fic Publications No. 144. Lyon: Interna-tional Agency for Research on Cancer; 1998. 500 p.
Desandes E, Clavel J, Berger C, et al. Cancer incidence among children in France, 1990-1999. Pediatr Blood Can-cer. 2004;43(7):749-57.
Pianovski MA, Maluf EM, de Carva-lho DS, et al. Mortality rate of adreno-cortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatr Blood Cancer. 2006;47(1):56-60.
Ribeiro, R.C.; Sandrini, F.; Figuei-redo, B. et al. An inherited p53 muta-tion that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl. Acad. Sci. USA, v.98, n.16, p.9330-9335, 2001.
Custodio G, Taques GR, Figueiredo BC, et al. Increased incidence of cho-roid plexus carcinoma due to the ger-mline TP53 R337H mutation in southern Brazil. PLoS One. 2011;6(3):e18015. doi:10.1371/journal.pone.0018015.
Legal EF, Ascurra M, Custódio G, Ayala HL, Monteiro M, Vega C, Fer-nández-Nestosa MJ, Vega S, Sade ER, Coelho IM, Ribeiro EM, Cavalli IJ, Fi-gueiredo BC. Prevalence of an inheri-ted cancer predisposition syndrome as-sociated with the germline TP53 R337H mutation in Paraguay. Cancer Epidemiol. 2015 Apr;39(2):166-9. doi:10.1016/j.canep.2015.01.005. Epub 2015 Feb 23. PMID: 25736369.
Wajchenberg BL, Lerario AC, Betti RTB. Tratado de endocrinologia clíni-ca. 2nd ed. São Paulo: AC Farmacêuti-ca; 2014. 804 p.
Fernández-Tresguerres JA, Ruiz C, Cachofeiro V, Cardinali DP, Escriche E, Gil-Loyzaga PE, et al., editors. Fisiolo-gía humana. 4th ed. New York: McGraw-Hill Education; 2016
Arriza JL, Weinberger C, Cerelli g, Glaser TM, Handelin BL, Housa DE, et al. Cloning of human mineralcorticoid receptor complementary DNA: structu-ral and functional kinship with the glu-corticoid receptor. Science. 1987 Jul; 237(4812):268-75
Payne, AH. Hales DB. Overview of steroidogenic cnzymes in the pathway from cholesterol to active steroid hor-mones. Endocrine Rewiews. 2004 Dec; 25(6):947-70
Mesiano S, Jaffe RB. Developmen-tal and functional biology of the prima-te fetal adrenal cortex. Endocr Rev. 1997;18(3):378-403.
Keegan CE, Hammer GD. Recent insights into organogenesis of the adre-nal cortex. Trends Endocrinol Metab. 2002;13(5):200-8.
Sucheston ME, Cannon MS. Deve-lopment of zonular patterns in the hu-man adrenal gland. J Morphol. 1968;126(4):477-91.
Costa TEJ, Gerber VKQ, Ibañez HC, Melanda VS, Parise IZS, Watanabe FM, et al. Cancers. 2019;11(11):1804.
Figueiredo BC, Sandrini R, Zam-betti GP, Pereira RM, Cheng C, Liu W, et al. Comparative genomic hybridiza-tion analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab. 1999;84(3):1116-21.
Custódio G, Almeida MQ, Fragoso MCBV, Mello MP, Figueiredo BC, Cas-tro G, et al. Molecular epidemiology of adrenocortical tumors in southern Bra-zil. Mol Cell Endocrinol. 2012 Mar 31;351(1):44-51.
West AN, Neale GA, Pounds S, et al. Gene expression profiling of chil-dhood adrenocortical tumors. Cancer Res. 2007;15:600-8.
Rosati R, Doghman M, Pianovski M, et al. High frequency of loss of he-terozygosity at 11p15 and IGF2 ove-rexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation. Cancer Genet Cytogenet. 2008 Oct;186(1):19-24.
Michalkiewicz E, Sandrini R, Fi-gueiredo B, et al. Clinical and outcome characteristics of children with adre-nocortical tumors: a report from the In-ternational Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004;22(5):838-45.
Latronico AC, Chrousos GP. Exten-sive personal experience: adrenocorti-cal tumors. J Clin Endocrinol Metab. 1997;82(5):1317-24.
Wajchenberg BL, Albergaria Pereira MA, Mendonça BB, et al. Adrenocorti-cal carcinoma: clinical and laboratory observations. Cancer. 2000;88(4):711-36.
Vierhapper H. Adrenocortical tu-mors: clinical symptoms and bioche-mical diagnosis. Eur J Radiol. 2002;41(2):88-94.
Liou LS, Kay R. Adrenocortical carcinoma in children. Review and re-cent innovations. Urol Clin North Am. 2000;27(3):403-21.
Custódio G, Komechen H, Figuei-redo FR, et al. Molecular epidemiology of adrenocortical tumors in southern Brazil. Mol Cell Endocrinol. 2012 Mar 31;351(1):44-51. Epub 2011 Oct 25.
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edi-tion. New York: Garland Science; 2002
Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979;278:261-3.
Linzer DIH, Levine AJ. Characteri-zation of a 54 K dalton cellular SV40 tumor antigen present in SV40-transformed cells and in infected em-bryonal carcinoma cells. Cell. 1979;1:43-52.
Aubrey BJ, Janic A, Chen Y, Chang C, Lieschke EC, Diepstraten ST, et al. Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development. Genes Dev. 2018 Nov 1;32(21-22):1420-9. doi: 10.1101/gad.314286.118. Epub 2018 Oct 26. PMID: 30366906; PMCID: PMC6217734.
Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413-31. doi:10.1016/j.cell.2009.04.037.
Steenman M, Westerveld A, Man-nens M. Genetics of Beckwith-Wiedemann syndrome-associated tu-mors: common genetic pathways. Ge-nes Chromosomes Cancer. 2000;28:1-13.
Gicquel C, Bertagna X, Schneid H, et al. Rearrangement at the 11p15 locus and overexpression of IGF-2 gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1994;78(6):1444-53.
Figueiredo BC, Cavalli LR, Pianovski MA, et al. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab. 2005;90(2):615-9.
Fragoso MCBV, Ferreira AM, Brandoni VB, Almeida MQ. Carcinoma de córtex suprarrenal. In: Sociedade Brasileira de Endocrinologia e Metabo-logia; Carvalho GA, Czepielewski MA, Meirelles R, organizadores. PROEN-DÓCRINO Programa de Atualização em Endocrinologia e Metabologia: Ci-clo 9. Porto Alegre: Artmed Panameri-cana; 2018. P. 91-124 (Sistema de Edu-cação Continuada à Distância, v. 3).
Young WF. Primary aldosteronism: diagnosis, screening, and management. J Clin Endocrinol Metab. 2007;92(11):4006-20.
Fassnacht M, Kroiss M. Adrenocor-tical carcinoma: management and trea-tment. Endocr Dev. 2017;31:42-52.
Merke DP, Bornstein SR. Congeni-tal adrenal hyperplasia. Lancet. 2005;365(9477):2125-36.
Gaujoux S, Bonnet P. Adrenal lesi-ons: imaging and clinical implications. Nat Rev Endocrinol. 2013;9(4):212-21.
Lenders JW, et al. Pheochromo-cytoma and paraganglioma: pathophysiology, diagnosis, and trea-tment. Endocr Rev. 2005;26(5):619-38.
Maris JM. Neuroblastoma: biologi-cal insights and clinical challenges. Nat Rev Cancer. 2010;10(5):317-28.
Puri P, et al. Adrenal tumors in children: A clinical review. *Pediatr Surg Int*. 2015;31(4):325-333.
Agha A, et al. Pediatric adrenal tu-mors: A review. *J Pediatr Hematol Oncol*. 2018;40(5):355-361.
Lalli E, Figueiredo BC. Pediatric adrenocortical tumors: what they can tell us on adrenal development and comparison with adult adrenal tumors. *Front Endocrinol (Lausanne)*. 2015 Feb 18;6:23. doi: 10.3389/fendo.2015.00023. PMID: 25741319; PMCID: PMC4332354.
Michalkiewicz E, Sandrini R, Fi-gueiredo B, et al. Clinical and outcome characteristics of children with adre-nocortical tumors: a report from the In-ternational Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004;22(5):838-45
Zancanella P, Pianovski MA, Oli-veira BH, Ferman S, Piovezan GC, Li-chtvan LL, Voss SZ, Stinghen ST, Cal-lefe LG, Parise GA, Santana MH, Fi-gueiredo BC. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical car-cinoma: mitotane monitoring and tu-mor regression. J Pediatr Hematol On-col. 2006 Aug;28(8):513-24. doi: 10.1097/01.mph.0000212965.52759.1c. PMID: 16912591.
Falcon-de Legal, EAM. Prevalência da mutação TP53 R337H em uma regi-ão de fronteira paraguaia. 2012. 82p. Dissertação (Mestrado em Biotecnolo-gia Aplicada à Saúde da Criança e do Adolescente) - Faculdades Pequeno Príncipe, Curitiba.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Edith Falcón de Legal, Marta Ascurra
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
